Compare ADMA Biologics Inc (ADMA) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Skyworks Solutions Inc — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while Skyworks Solutions Inc trades at $59.03 (market cap $8.99B). The key difference: Skyworks Solutions Inc is far larger — about 4.2× ADMA Biologics Inc's market cap, and Skyworks Solutions Inc pays a 4.75% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | SWKS | |
|---|---|---|
Market Cap | $2.13B | $8.99B |
Sector | Health | Technology |
52-Week High | $20.38 | $83.40 |
52-Week Low | $7.60 | $52.50 |
Enterprise Value | $2.20B | $8.76B |
Dividend Yield | — | 4.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Skyworks Solutions (SWKS) trades at $59.76, down 4.48% on the day, with a bearish technical signal despite recent earnings beats. The company shows declining revenue and net income margins over recent years, though profitability metrics like gross margin remain solid at 41.08%. Recent news highlights product launches in EV and AI infrastructure alongside ongoing legal investigations into corporate governance.
The outlook is mixed: strong analyst buy consensus (60%) and a $72.56 price target suggest upside, but declining cash flow and revenue trends pose risks. Investment opportunity lies in market diversification and new tech segments, balanced against margin pressure and legal overhangs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
